These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11038636)

  • 1. CMV in kidney transplantation: a single center experience over 22 years.
    Nashan B; Lück R; Kliem V; Brunkhorst R; Schlitt HJ; Klempnauer J
    Clin Transpl; 1999; ():181-8. PubMed ID: 11038636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
    Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
    Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study.
    Moreno de la Higuera Díaz MA; Calvo Romero N; Sánchez-Fructuoso A; Conesa J; Marques Vidas M; Prats D; Barrientos Guzmán A
    Transplant Proc; 2007 Sep; 39(7):2231-2. PubMed ID: 17889147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
    Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines.
    Dmitrienko S; Balshaw R; Machnicki G; Shapiro RJ; Keown PA
    Transplantation; 2009 Feb; 87(4):570-7. PubMed ID: 19307796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.
    Taherimahmoudi M; Ahmadi H; Baradaran N; Montaser-Kouhsari L; Salem S; Mehrsai A; Kalantar E; Jahani Y; Pourmand G
    Transplant Proc; 2009 Sep; 41(7):2841-4. PubMed ID: 19765452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gancyclovir prophylaxis in high risk patients.
    Campino A
    Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
    Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
    Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
    Boucher A; Lord H; Collette S; Morin M; Dandavino R
    Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 20. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.